Holen Sie sich die Stockscreener-App
3.44
0.86%
-0.03
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms - TipRanks
Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026 - TradingView
Insight Molecular Diagnostics Inc. Share PriceIMDX, RNS News, Articles, Quotes, & Charts (NASDAQ:IMDX) - proactiveinvestors.com
Insight Molecular (IMDX) shifts Chronix earnout to CNI Monitor test - Stock Titan
Insight Molecular Diagnostics Inc.(NasdaqCM: IMDX) added to S&P Global BMI Index - marketscreener.com
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Insight Molecular Diagnostics (IMDX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Medicare policy boosts iMDx transplant testing frequency - scanx.trade
Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et
iMDx executives are set to meet investors in New York - Stock Titan
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference - GlobeNewswire
IMDX Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.73%Earnings Per Share - careplusvn.com
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria
Insight (IMDX) Quarter in Focus: Profit Per Share Clears Its Benchmark on the Day; Shares Move 0.93% Higher on the DayWeak Earnings Momentum - dars.gov.et
Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn
Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics advances heart tr... - Pluang
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Rest-Of-Europe Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - marketsandmarkets.com
Insight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform - scanx.trade
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com Nigeria
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com
Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa
Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com
IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila Times
IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 55% EPS SurpriseEPS Surprise History - dars.gov.et
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in FocusMedian Line - careplusvn.com
IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Earnings Preview: IMDX to Report Financial Results Post-market on August 10 - Moomoo
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - The Manila Times
IMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - marketscreener.com
iMDx to Release Second Quarter Results on August 10, 2026 - GlobeNewswire
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):